Literature DB >> 3922501

Increased severity and morbidity of acute hepatitis in drug abusers with simultaneously acquired hepatitis B and hepatitis D virus infections.

A G Shattock, F M Irwin, B M Morgan, I B Hillary, M G Kelly, J F Fielding, D A Kelly, D G Weir.   

Abstract

Hepatitis D virus (delta agent) markers were present in 111 (36%) of 308 intravenous drug abusers who were positive for hepatitis B surface antigen (HBsAg), 52 of these having hepatitis D virus antigenaemia. IgM antibody to hepatitis B core antigen (anti-HBc IgM) was present in 92 out of 95 subjects tested, indicating that hepatitis D virus and hepatitis B virus infections had been acquired simultaneously. Hepatitis D virus markers were present in three out of four patients with fulminant hepatitis, and in 80 of 223 (36%) with mild or moderate hepatitis compared with four of 29 (14%) of those who were asymptomatic. These proportional differences were significant (p less than 0.001). Hepatitis D virus markers were present in twice as many patients positive for anti-HBc IgM requiring admission to hospital with acute hepatitis compared with outpatients attending a drug treatment centre. Tests on one patient showed complete disappearance of HBsAg, but hepatitis D antigen (HDAg or delta antigen) and hepatitis B e antigen (HBeAg) were still present in serum samples. All five patients with chronic active hepatitis had hepatitis D antibody (anti-HD) compared with seven of 24 (29%) with chronic persistent hepatitis (p = 0.008). Blocking anti-HD persisted for long periods after simultaneous infections with hepatitis B virus and hepatitis D virus but at lower titres than in patients with chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922501      PMCID: PMC1415608          DOI: 10.1136/bmj.290.6479.1377

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  20 in total

1.  Does delta agent contribute to fulminant hepatitis?

Authors:  E Tabor; A Ponzetto; J L Gerin; R J Gerety
Journal:  Lancet       Date:  1983-04-02       Impact factor: 79.321

2.  Exacerbation of chronic liver disease due to hepatitis B surface antigen after delta infection.

Authors:  A G Shattock; J F Fielding
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-16

3.  Delta agent and hepatitis B.

Authors:  A G Redeker
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

4.  Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen.

Authors:  O Crivelli; M Rizzetto; C Lavarini; A Smedile; J L Gerin
Journal:  J Clin Microbiol       Date:  1981-08       Impact factor: 5.948

5.  Development of an enzyme-linked immunosorbent assay (ELISA) for hepatitis B e antigen and antibody.

Authors:  A M Smith; R S Tedder
Journal:  J Virol Methods       Date:  1981-07       Impact factor: 2.014

6.  Epidemic hepatitis B with delta-antigenaemia among Dublin drug-abusers.

Authors:  A G Shattock; M G Kelly; J Fielding; Y Arthurs
Journal:  Ir J Med Sci       Date:  1982-11       Impact factor: 1.568

7.  Influence of delta infection on severity of hepatitis B.

Authors:  A Smedile; P Farci; G Verme; F Caredda; A Cargnel; N Caporaso; P Dentico; C Trepo; P Opolon; A Gimson; D Vergani; R Williams; M Rizzetto
Journal:  Lancet       Date:  1982-10-30       Impact factor: 79.321

8.  Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: its correlation with liver biopsy diagnosis.

Authors:  S Govindarajan; G C Kanel; R L Peters
Journal:  Gastroenterology       Date:  1983-07       Impact factor: 22.682

9.  Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy.

Authors:  A Smedile; C Lavarini; P Farci; S Aricò; G Marinucci; P Dentico; G Giuliani; A Cargnel; C Del Vecchio Blanco; M Rizzetto
Journal:  Am J Epidemiol       Date:  1983-02       Impact factor: 4.897

10.  Clinical aspects of delta infection.

Authors:  T Moestrup; B G Hansson; A Widell; E Nordenfelt
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-08
View more
  14 in total

1.  Prevalence of hepatitis delta (delta) virus infection. A seroepidemiologic study.

Authors:  K M DeCock; B Jones; S Govindarajan; A G Redeker
Journal:  West J Med       Date:  1988-03

2.  Acute hepatitis B and hepatitis D co-infection in the Stockholm region in the 1970s and 1980s--a comparison.

Authors:  G Lindh; L Mattsson; M von Sydow; O Weiland
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

Review 3.  Serological responses to HBV infection.

Authors:  E A Fagan; R Williams
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

Review 4.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

5.  The evolving spectrum of viral hepatitis.

Authors:  D G Weir
Journal:  Ir J Med Sci       Date:  1989-08       Impact factor: 1.568

6.  Estimation of the secondary attack rate for delta hepatitis coinfection among injection drug users.

Authors:  C Poulin; T Gyorkos; L Joseph
Journal:  Can J Infect Dis       Date:  1993-01

7.  Possible reactivation of hepatitis D with chronic delta antigenaemia by human immunodeficiency virus.

Authors:  A G Shattock; H Finlay; I B Hillary
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-27

8.  Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains.

Authors:  E Flodgren; S Bengtsson; M Knutsson; E A Strebkova; A H Kidd; O A Alexeyev; K Kidd-Ljunggren
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

9.  Introduction of hepatitis delta virus into Polish drug community.

Authors:  T Laskus; M Radkowski; E Lupa; J Cianciara; J Slusarczyk; G Halama; A Horban
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

10.  Prevalence of HBV, HDV and HIV infections among intravenous drug addicts in Greece.

Authors:  A Roumeliotou-Karayannis; N Tassopoulos; E Karpodini; E Trichopoulou; M Kotsianopoulou; G Papaevangelou
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.